Erika Nichols, PA
Medical · Nashville, TNNPI 1295225415
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 282 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 282 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$899
- AstraZeneca$877
- AbbVie$625
- Exact Sciences$218
- Astellas Pharma US Inc$205
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,85599%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 52 | $1,039 |
| Lilly USA, LLC | 39 | $899 |
| AstraZeneca | 41 | $877 |
| AbbVie | 27 | $625 |
| Exact Sciences | 11 | $218 |
| Astellas Pharma US Inc | 7 | $205 |
| Amgen | 10 | $190 |
| Boehringer Ingelheim | 10 | $177 |
| Abbott | 9 | $169 |
| Pfizer | 7 | $158 |
| Corcept Therapeutics | 5 | $124 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $119 |
| Johnson & Johnson | 6 | $108 |
| GSK | 6 | $106 |
| Bayer | 6 | $97 |
| Myriad Women's Health, Inc. | 2 | $91 |
| Esperion Therapeutics, Inc. | 5 | $79 |
| Dexcom, Inc. | 3 | $77 |
| Edwards Lifesciences | 3 | $68 |
| Bausch Health US, LLC | 3 | $57 |
| Phathom Pharmaceuticals, Inc. | 3 | $54 |
| Axsome Therapeutics, Inc. | 2 | $53 |
| Idorsia Pharmaceuticals US Inc | 3 | $50 |
| Eisai Inc. | 2 | $46 |
| Nestle Healthcare Nutrition Inc. | 2 | $35 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| Seqirus USA Inc | 2 | $31 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| Radius Health, Inc. | 1 | $18 |
| Lucid Diagnostics Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Cequr Corporation | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Merck | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,930 in reported general payments places this provider in the 90th percentile of 480 medical providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $50,344 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $38,538 |
| RybelsusSemaglutide | 17 | $32,590 |
| JardianceEmpagliflozin | 27 | $29,420 |
| FarxigaDapagliflozin Propanediol | 19 | $27,204 |
| MounjaroTirzepatide | 21 | $22,848 |
| EliquisApixaban | 16 | $16,562 |
| XareltoRivaroxaban | 14 | $10,791 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $9,890 |
| Atorvastatin Calcium | 182 | $2,371 |
| Nebivolol Hcl | 24 | $1,866 |
| Doxepin Hcl | 12 | $1,641 |
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 17 | $1,559 |
| Valsartan | 36 | $1,539 |
| Amlodipine Besylate | 188 | $1,372 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,039 | $82,93351 claims |
| GSKTrelegy Ellipta | $106 | $38,53839 claims |
| Boehringer IngelheimJardiance | $177 | $29,42027 claims |
| AstraZenecaFarxiga | $877 | $27,20419 claims |
| Lilly USA, LLCMounjaro | $899 | $22,84821 claims |
| PfizerEliquis | $158 | $16,56216 claims |
| Johnson & JohnsonXarelto | $108 | $10,79114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 480 medical providers in Tennessee.
Other medical in Nashville
- Evan HatfillNashville$18K
- Scarlett FordNashville$12K
- Reema PatelNashville$7K
- Cassandra GriebNashville$6K
- Maria WoodChattanooga$130K
- Alyssa JamesonFranklin$65K
- Melissa LambertHendersonville$47K
- Stephanie HowardKnoxville$18K
- Meredith McDanielChattanooga$17K
- Janet BreedingKnoxville$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.